Design, Development, Characterization of Solid Lipid Nanoparticles for Oral Administration

Abstract

A high potential for drug delivery has been attributed to particulate drug carriers, especially small particles such as micro particles and colloidal system in nanometer range. Controlled and targeted delivery is one the most enviable requirements from a carrier, which involves the multidisciplinary site-specific or targeted approach. Nanoparticles have important potential applications for the administration of therapeutic and diagnostic agents. Nanoparticulate drug delivery system may offer plenty of advantages over conventional dosage forms which include improved, reduced toxicity, enhanced biodistribution and improved patient compliance. Pharmaceutical Nanoparticles are subnano sizes structures, which contain drug or bioactive substances within them and are constituted of several tens or hundreds of atoms or molecules and morphologies (amorphous, crystalline, spherical, needles). Montelukast sodium (MKS) is a potent, orally active, and has high affinity and selectively binds to the cysteinyl leukotriene 1 (CysLT1) receptor as compared to the prostanoid, cholinergic or β-adrenergic airway receptor. The main drawback of conventional montelukast formulation is that it undergoes hepatic first pass metabolism. The Cumulative % drug release with respect to time was found to be 95.38% for the optimized batch. From the oral bioavailability study it became evident that enhancement in the bioavailability of MKS was observed after drug-loaded SLNs have been administered in in vivo.